Nuwellis (NUWE) announced it has signed a non-binding letter of intent, LOI, to acquire Rendiatech, an Israeli-based medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies. The proposed acquisition is expected to support Nuwellis’ strategy to expand its current technology platform beyond ultrafiltration by potentially adding continuous renal health monitoring technologies that provide clinicians with earlier insight into fluid status and kidney function. As part of the proposed transaction, Nuwellis would add to its product portfolio Rendiatech’s Clarity RMS, an FDA-cleared critical care monitoring system that continuously measures urine flow and automatically sends data and alerts of fluctuations to medical staff in real-time. Rendiatech’s next-generation system, Clarity Prime, is currently in development to advance urine monitoring capabilities, offering clinicians critical insights into renal and cardiovascular health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis, Inc. Reports Q2 2025 Financial Results
- Nuwellis reports Q2 EPS ($60.99) vs ($791.82) last year
- NUWE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Nuwellis to exit international operations to accelerate U.S. revenue growth
- Nuwellis postpones Q2 earnings release, conference call